Literature DB >> 25226005

Reversing facial fillers: interactions between hyaluronidase and commercially available hyaluronic-acid based fillers.

Veena Rao, Sulene Chi, Julie Woodward.   

Abstract

INTRODUCTION: Hyaluronidase (HA) degrades hyaluronic acid, allowing flexibility in the use of hyaluronic acid-based fillers commonly used in facial correction. Potentially differing properties of available hyaluronidases and fillers may influence their interaction, leading to important differences in ultimate cosmetic results. This study examines the physical properties of various fillers after exposure to commonly available hyaluronidases in vitro to better inform their in vivo clinical use.
METHODS: Four commonly used HA fillers were exposed to varying concentrations of Vitrase (ovine testicular hyaluronidase) and Hylenex (human recombinant hyaluronidase) in vitro. The gross properties of these fillers were then observed to evaluate time- and dose-response; photographs were obtained to allow visual comparison at 1 minute and 5 minutes post-exposure.
RESULTS: At a concentration of 0.1 mL Vitrase to 0.2 mL filler, Restylane dissipated most followed by Juvéderm; Belotero most retained its form. Hylenex at the same concentration showed similar results, again affecting Restylane most and Belotero least. Response to treatment with both hyaluronidases increased substantially over time, increasing progressively from exposure to 5 minutes post-exposure. When exposed to Hylenex at 15 U and 30 U to 0.2 mL filler, Belotero retained its form most, followed by Juvéderm, Juvéderm Voluma, and then Restylane. The effects on filler structure increased with 30 U concentration vs 15 U concentration of Hylenex. DISCUSSION: Available hyaluronidases and HA fillers appear to have differing physical properties that influence their interaction in a time and dose-dependent manner. Knowledge of the ways in which specific fillers interact with different hyaluronidases may help achieve desired cosmesis when aiming to adjust delicate facial fillers.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25226005

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  8 in total

1.  This month's guideline: The Use of Hyaluronidase in Aesthetic Practice (v2.4).

Authors:  Martyn King; Cormac Convery; Emma Davies
Journal:  J Clin Aesthet Dermatol       Date:  2018-06-01

2.  Histological and Quantitative Appraisal of the Intradermal and Subcutaneous Distribution of the Hyaluronic Acid Injected into the Nasolabial Fold.

Authors:  Antonio Carlos Abramo; Marcio Scartozzoni; Romulo Sgarbi
Journal:  Aesthetic Plast Surg       Date:  2020-03-20       Impact factor: 2.326

Review 3.  Clinical Applications of Hyaluronidase.

Authors:  Gregor Cornelius Weber; Bettina Alexandra Buhren; Holger Schrumpf; Johannes Wohlrab; Peter Arne Gerber
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

4.  Periorbital Injectables: Understanding and Avoiding Complications.

Authors:  Catherine J Hwang
Journal:  J Cutan Aesthet Surg       Date:  2016 Apr-Jun

5.  Hyaluronidase: An overview of its properties, applications, and side effects.

Authors:  Hyunwook Jung
Journal:  Arch Plast Surg       Date:  2020-07-15

6.  Standardized in vitro analysis of the degradability of hyaluronic acid fillers by hyaluronidase.

Authors:  Bettina Alexandra Buhren; Holger Schrumpf; Edwin Bölke; Kai Kammers; Peter Arne Gerber
Journal:  Eur J Med Res       Date:  2018-08-20       Impact factor: 2.175

7.  Complication Management following Rejuvenation Procedures with Hyaluronic Acid Fillers-an Algorithm-based Approach.

Authors:  Philippe Snozzi; Jani A J van Loghem
Journal:  Plast Reconstr Surg Glob Open       Date:  2018-12-17

Review 8.  Hyaluronic acid fillers with cohesive polydensified matrix for soft-tissue augmentation and rejuvenation: a literature review.

Authors:  Adri D Prasetyo; Welf Prager; Mark G Rubin; Ernesto A Moretti; Andreas Nikolis
Journal:  Clin Cosmet Investig Dermatol       Date:  2016-09-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.